You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

~ Buy the QTERN (dapagliflozin; saxagliptin hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

QTERN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Qtern, and what generic alternatives are available?

Qtern is a drug marketed by Astrazeneca Ab and is included in two NDAs. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has three hundred and six patent family members in forty-eight countries.

The generic ingredient in QTERN is dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride. There are twenty-six drug master file entries for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Qtern

Qtern was eligible for patent challenges on January 8, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 16, 2029. This may change due to patent challenges or generic licensing.

There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for QTERN
Drug Prices for QTERN

See drug prices for QTERN

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for QTERN
Generic Entry Date for QTERN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for QTERN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
QTERN Tablets dapagliflozin; saxagliptin hydrochloride 5 mg/5 mg 209091 1 2020-07-29
QTERN Tablets dapagliflozin; saxagliptin hydrochloride 10 mg/5 mg 209091 5 2018-01-08

US Patents and Regulatory Information for QTERN

QTERN is protected by eleven US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of QTERN is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting QTERN

C-aryl glucoside SGLT2 inhibitors and method
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Crystal structures of SGLT2 inhibitors and processes for preparing same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical formulations containing an SGLT2 inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical formulations containing an SGLT2 inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Pharmaceutical formulations containing an SGLT2 inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN

Pharmaceutical formulations containing an SGLT2 inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN

Crystal structures of SGLT2 inhibitors and processes for preparing same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Crystal structures of SGLT2 inhibitors and processes for preparing same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN

Crystal structures of SGLT2 inhibitors and processes for preparing same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN

Coated tablet formulation and method
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical formulations containing an SGLT2 inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-004 May 2, 2019 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-003 May 2, 2019 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-002 May 2, 2019 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-003 May 2, 2019 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Astrazeneca Ab QTERNMET XR dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride TABLET, EXTENDED RELEASE;ORAL 210874-002 May 2, 2019 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Astrazeneca Ab QTERN dapagliflozin; saxagliptin hydrochloride TABLET;ORAL 209091-002 May 2, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for QTERN

International Patents for QTERN

When does loss-of-exclusivity occur for QTERN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1730
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 07265246
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0713544
Estimated Expiration: ⤷  Try a Trial

Patent: 2017015106
Estimated Expiration: ⤷  Try a Trial

Patent: 2017021516
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 53344
Estimated Expiration: ⤷  Try a Trial

Patent: 24318
Estimated Expiration: ⤷  Try a Trial

Patent: 85797
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 07001915
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1479287
Estimated Expiration: ⤷  Try a Trial

Patent: 3145773
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 60299
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0141007
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 15738
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 69374
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 8229
Estimated Expiration: ⤷  Try a Trial

Patent: 0428
Estimated Expiration: ⤷  Try a Trial

Patent: 8259
Estimated Expiration: ⤷  Try a Trial

Patent: 5999
Estimated Expiration: ⤷  Try a Trial

Patent: 0900066
Estimated Expiration: ⤷  Try a Trial

Patent: 1171333
Estimated Expiration: ⤷  Try a Trial

Patent: 1490902
Estimated Expiration: ⤷  Try a Trial

Patent: 1791254
Estimated Expiration: ⤷  Try a Trial

Patent: 2091391
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 69374
Estimated Expiration: ⤷  Try a Trial

Patent: 57918
Estimated Expiration: ⤷  Try a Trial

Patent: 45466
Estimated Expiration: ⤷  Try a Trial

Patent: 63807
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 27359
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 5882
Estimated Expiration: ⤷  Try a Trial

Patent: 4180
Estimated Expiration: ⤷  Try a Trial

Patent: 4181
Estimated Expiration: ⤷  Try a Trial

Patent: 4182
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 13889
Estimated Expiration: ⤷  Try a Trial

Patent: 66651
Estimated Expiration: ⤷  Try a Trial

Patent: 37187
Estimated Expiration: ⤷  Try a Trial

Patent: 09545525
Estimated Expiration: ⤷  Try a Trial

Patent: 13209394
Estimated Expiration: ⤷  Try a Trial

Patent: 15071636
Estimated Expiration: ⤷  Try a Trial

Patent: 16172758
Estimated Expiration: ⤷  Try a Trial

Patent: 17222681
Estimated Expiration: ⤷  Try a Trial

Patent: 19059779
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 8566
Estimated Expiration: ⤷  Try a Trial

Patent: 3930
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 9143
Estimated Expiration: ⤷  Try a Trial

Patent: 7155
Estimated Expiration: ⤷  Try a Trial

Patent: 08015377
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 4346
Estimated Expiration: ⤷  Try a Trial

Patent: 9190
Estimated Expiration: ⤷  Try a Trial

Patent: 9195
Estimated Expiration: ⤷  Try a Trial

Patent: 9202
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 6828
Estimated Expiration: ⤷  Try a Trial

Patent: 085169
Estimated Expiration: ⤷  Try a Trial

Patent: 221233
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 080349
Estimated Expiration: ⤷  Try a Trial

Patent: 120776
Estimated Expiration: ⤷  Try a Trial

Philippines

Patent: 012500168
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 69374
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 69374
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 638
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 2741
Estimated Expiration: ⤷  Try a Trial

Patent: 201402181S
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 69374
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0810475
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1493102
Estimated Expiration: ⤷  Try a Trial

Patent: 090023643
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 21665
Estimated Expiration: ⤷  Try a Trial

Patent: 59862
Estimated Expiration: ⤷  Try a Trial

Patent: 69130
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 21245
Estimated Expiration: ⤷  Try a Trial

Patent: 66876
Estimated Expiration: ⤷  Try a Trial

Patent: 19528
Estimated Expiration: ⤷  Try a Trial

Patent: 0811127
Estimated Expiration: ⤷  Try a Trial

Patent: 1406743
Estimated Expiration: ⤷  Try a Trial

Patent: 1509927
Estimated Expiration: ⤷  Try a Trial

Patent: 1546054
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 765
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QTERN around the world.

Country Patent Number Title Estimated Expiration
Lithuania 2508188 ⤷  Try a Trial
Japan 2005531588 ⤷  Try a Trial
New Zealand 518029 C-aryl glucoside SGLT2 inhibitors ⤷  Try a Trial
Mexico 339143 SOLVATOS Y COMPLEJOS CRISTALINOS DE LOS DERIVADOS DE (1S)-1,5-ANHIDRO-1-C-(3-((FENIL)METIL)FENIL)-D-GLUCITOL CON AMINOACIDOS COMO INHIBIDORES DE SGLT2 PARA EL TRATAMIENTO DE LA DIABETES. (CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES.) ⤷  Try a Trial
Russian Federation 2489151 ФАРМАЦЕВТИЧЕСКАЯ КОМБИНАЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР SGLT2 (PHARMACEUTICAL COMBINATION CONTAINING SGLT2 INHIBITOR) ⤷  Try a Trial
Russian Federation 2006146971 ТАБЛЕТКА С ПОКРЫТИЕМ ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for QTERN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2139494 132020000000115 Italy ⤷  Try a Trial PRODUCT NAME: SAXAGLIPTIN E DAPAGLIFLOZIN(QTERN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1108, 20160719
1506211 300677 Netherlands ⤷  Try a Trial PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
1261586 SPC/GB10/001 United Kingdom ⤷  Try a Trial PRODUCT NAME: SAXAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF INCLUDING SAXAGLIPTIN HYDROCHLORIDE; REGISTERED: UK EU/1/09/545/001 20091001; UK EU/1/09/545/002 20091001; UK EU/1/09/545/003 20091001; UK EU/1/09/545/004 20091001; UK EU/1/09/545/005 20091001; UK EU/1/09/545/006 20091001; UK EU/1/09/545/007 20091001; UK EU/1/09/545/008 20091001; UK EU/1/09/545/009 20091001; UK EU/1/09/545/010 20091001
1506211 SPC/GB13/021 United Kingdom ⤷  Try a Trial PRODUCT NAME: DAPAGLIFLOZIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/12/795/001 20121114; UK EU/1/12/795/002 20121114; UK EU/1/12/795/003 20121114; UK EU/1/12/795/004 20121114; UK EU/1/12/795/005 20121114; UK EU/1/12/795/006 20121114; UK EU/1/12/795/007 20121114; UK EU/1/12/795/008 20121114; UK EU/1/12/795/009 20121114; UK EU/1/12/795/010 20121114
1506211 13C0022 France ⤷  Try a Trial PRODUCT NAME: DAPAGLIFLOZINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/795/001 20121112
1506211 136 5005-2013 Slovakia ⤷  Try a Trial PRODUCT NAME: DAPAGLIFLOZIN; FIRST REGISTRATION NO/DATE: EU/1/12/795/001, EU/1/12/795/002, EU/1/12/795/003, EU/1/12/795/004, EU/1/12/795/005, EU/1/12/795/006, EU/1/12/795/007, EU/1/12/795/007, EU/1/12/795/008, EU/1/12/795/009, EU/1/12/795/010 20121112
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.